Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.

Carén H, Djos A, Nethander M, Sjöberg RM, Kogner P, Enström C, Nilsson S, Martinsson T.

BMC Cancer. 2011 Feb 11;11:66. doi: 10.1186/1471-2407-11-66.

2.
3.

Genome-wide promoter methylation analysis in neuroblastoma identifies prognostic methylation biomarkers.

Decock A, Ongenaert M, Hoebeeck J, De Preter K, Van Peer G, Van Criekinge W, Ladenstein R, Schulte JH, Noguera R, Stallings RL, Van Damme A, Laureys G, Vermeulen J, Van Maerken T, Speleman F, Vandesompele J.

Genome Biol. 2012 Oct 3;13(10):R95. doi: 10.1186/gb-2012-13-10-r95.

4.

EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma.

Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NK, Gerald WL, Esteller M.

Cancer Res. 2005 Apr 1;65(7):2565-71.

5.

Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.

Olsson M, Beck S, Kogner P, Martinsson T, Carén H.

Epigenetics. 2016;11(1):74-84. doi: 10.1080/15592294.2016.1138195. Epub 2016 Jan 19.

6.

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas.

Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, Kolla V, Kim J, Zhao H, Pawel BR, London WB, Maris JM, White PS, Brodeur GM.

J Natl Cancer Inst. 2008 Jul 2;100(13):940-9. doi: 10.1093/jnci/djn176. Epub 2008 Jun 24.

7.

A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression.

Vallot C, Stransky N, Bernard-Pierrot I, Hérault A, Zucman-Rossi J, Chapeaublanc E, Vordos D, Laplanche A, Benhamou S, Lebret T, Southgate J, Allory Y, Radvanyi F.

J Natl Cancer Inst. 2011 Jan 5;103(1):47-60. doi: 10.1093/jnci/djq470. Epub 2010 Dec 20.

8.

Genome-wide DNA methylation analysis identifies MEGF10 as a novel epigenetically repressed candidate tumor suppressor gene in neuroblastoma.

Charlet J, Tomari A, Dallosso AR, Szemes M, Kaselova M, Curry TJ, Almutairi B, Etchevers HC, McConville C, Malik KT, Brown KW.

Mol Carcinog. 2017 Apr;56(4):1290-1301. doi: 10.1002/mc.22591. Epub 2016 Nov 29.

9.

The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.

Djos A, Martinsson T, Kogner P, Carén H.

Mol Cancer. 2012 Jun 13;11:40. doi: 10.1186/1476-4598-11-40.

10.

Genome-wide analysis of epigenetic silencing identifies BEX1 and BEX2 as candidate tumor suppressor genes in malignant glioma.

Foltz G, Ryu GY, Yoon JG, Nelson T, Fahey J, Frakes A, Lee H, Field L, Zander K, Sibenaller Z, Ryken TC, Vibhakar R, Hood L, Madan A.

Cancer Res. 2006 Jul 1;66(13):6665-74.

11.

Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.

Wong CM, Ng YL, Lee JM, Wong CC, Cheung OF, Chan CY, Tung EK, Ching YP, Ng IO.

Hepatology. 2007 May;45(5):1129-38.

PMID:
17464989
12.

DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights.

Gómez S, Castellano G, Mayol G, Suñol M, Queiros A, Bibikova M, Nazor KL, Loring JF, Lemos I, Rodríguez E, de Torres C, Mora J, Martín-Subero JI, Lavarino C.

Epigenomics. 2015 Oct;7(7):1137-53. doi: 10.2217/epi.15.49. Epub 2015 Jun 12.

13.

Genome-wide transcriptional response to 5-aza-2'-deoxycytidine and trichostatin a in multiple myeloma cells.

Heller G, Schmidt WM, Ziegler B, Holzer S, Müllauer L, Bilban M, Zielinski CC, Drach J, Zöchbauer-Müller S.

Cancer Res. 2008 Jan 1;68(1):44-54. doi: 10.1158/0008-5472.CAN-07-2531.

14.

Genome-wide DNA methylation profiling of chronic lymphocytic leukemia allows identification of epigenetically repressed molecular pathways with clinical impact.

Tong WG, Wierda WG, Lin E, Kuang SQ, Bekele BN, Estrov Z, Wei Y, Yang H, Keating MJ, Garcia-Manero G.

Epigenetics. 2010 Aug 16;5(6):499-508. Epub 2010 Aug 16.

15.

Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis.

Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A, Kiviat N.

Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):114-23.

16.

Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma.

Margetts CD, Morris M, Astuti D, Gentle DC, Cascon A, McRonald FE, Catchpoole D, Robledo M, Neumann HP, Latif F, Maher ER.

Endocr Relat Cancer. 2008 Sep;15(3):777-86. doi: 10.1677/ERC-08-0072. Epub 2008 May 22.

17.

Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.

Yang Q, Zage P, Kagan D, Tian Y, Seshadri R, Salwen HR, Liu S, Chlenski A, Cohn SL.

Clin Cancer Res. 2004 Dec 15;10(24):8493-500.

18.

Comparative epigenomics of human and mouse mammary tumors.

Demircan B, Dyer LM, Gerace M, Lobenhofer EK, Robertson KD, Brown KD.

Genes Chromosomes Cancer. 2009 Jan;48(1):83-97. doi: 10.1002/gcc.20620.

19.

Identification of novel target genes by an epigenetic reactivation screen of renal cancer.

Ibanez de Caceres I, Dulaimi E, Hoffman AM, Al-Saleem T, Uzzo RG, Cairns P.

Cancer Res. 2006 May 15;66(10):5021-8.

20.

Transcriptional silencing of the TMS1/ASC tumour suppressor gene by an epigenetic mechanism in hepatocellular carcinoma cells.

Zhang C, Li H, Zhou G, Zhang Q, Zhang T, Li J, Zhang J, Hou J, Liew CT, Yin D.

J Pathol. 2007 Jun;212(2):134-42.

PMID:
17471463

Supplemental Content

Support Center